Phase4 Partners

Long known as one of the leading life science venture capital firms based in Europe, Phase4 Partners, formerly known as Phase4 Ventures, has more recently expanded its mission to include a range of innovative investment vehicles to meet the needs of major pharmaceutical companies as well as sophisticated private and institutional investors from around the world. Founded in 1999 with its home office in London, Phase4 has invested over $400 million in 24 companies in both Europe and the US, including such notable successes as Pharmion, Arakis, Proteolix, Albireo, and OncoMed (NASDAQ: OMED). Phase4 is particularly proud of its key role in funding the development of breakthrough products such as Kyprolis (acquired by Onyx when it purchased Proteolix); Ultibro Breezhaler (a Novartis product originally developed by Arakis); and Vidaza and Thalomid (both acquired by Celgene when it purchased Pharmion); as well as important advances now in clinical trials including OncoMed’s line of innovative products directed at blocking cancer stem cells and Albireo’s elobixibat, now in Phase III studies being conducted by Albireo’s partner Ferring. All of these products offer significant improvements in the treatment of serious diseases while having the potential to generate large profits for the companies involved as well as our investors. Phase4 is a member of the British Private Equity and Venture Capital Association (BVCA), and the European Private Equity and Venture Capital Association (EVCA).